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Abstract
Recently, ADAMTS19 was identified as a novel causative gene for autosomal reces-
sive heart valve disease (HVD), affecting mainly the aortic and pulmonary valves.
Exome sequencing and data repository (CentoMD) analyses were performed to iden-
tify patients with ADAMTS19 variants (two families). A third family was recognized
based on cardiac phenotypic similarities and SNP array homozygosity. Three novel
loss of function (LoF) variants were identified in six patients from three families. Clini-
cally, all patients presented anomalies of the aortic/pulmonary valves, which included
thickening of valve leaflets, stenosis and insufficiency. Three patients had (recurrent)
subaortic membrane, suggesting that ADAMTS19 is the first gene identified related
to discrete subaortic stenosis. One case presented a bi-commissural pulmonary valve.
All patients displayed some degree of atrioventricular valve insufficiency. Other car-
diac anomalies included atrial/ventricular septal defects, persistent ductus arteriosus,
and mild dilated ascending aorta. Our findings confirm that biallelic LoF variants in
ADAMTS19 are causative of a specific and recognizable cardiac phenotype. We rec-
ommend considering ADAMTS19 genetic testing in all patients with multiple semilu-
nar valve abnormalities, particularly in the presence of subaortic membrane.
ADAMTS19 screening in patients with semilunar valve abnormalities is needed to
estimate the frequency of the HVD related phenotype, which might be not so rare.
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1 | INTRODUCTION
The human heart is one of the first organs to function during embryonic
life. In fact, proper function of the cardiovascular system is critical for
embryonic survival.1 The complex stages of cardiovascular morphogen-
esis include heart tube formation and looping followed by chamber for-
mation, remodeling and formation of the arterial trunks.1,2 The process
requires a delicate balance that if perturbed, usually leads to heart
defects.1
Congenital heart disease (CHD) is the most common form of struc-
tural birth defects observed in humans,3 with bicuspid aortic valve (BAV)
being the most common CHD.4 BAV may be asymptomatic and
undetected in early life but poses a risk for serious complications and
sudden cardiac death later in life.5 The extreme clinical variability,
reduced penetrance, and suspected genetic heterogeneity have compli-
cated the identification of genes involved in non-syndromic CHD, with
only a limited number of genes identified to date.6-9
Recently, Wünnemann et al identified biallelic loss of function (LoF)
variants inADAMTS19 as causative for heart valve disease (HVD), affect-
ing mainly the aortic and pulmonary valves as described in four patients
from two families.10 Furthermore, 38%of homozygousAdamts19 knock-
out mice presented progressive aortic valve disease, characterized by
aortic valve stenosis and insufficiency. Histological examination of the
dysfunctional aortic valve from knockout mice showed disorganization
of the extracellular matrix (ECM), with thickened valve leaflets and colla-
gen deposition.10 Single cell RNA-sequencing (scRNA) identified the Klf2
shear stress signature, with apparent valvular interstitial cells to endocar-
dial signaling. The authors concluded that loss of Adamts19 perturbs
shear stress signaling in endothelial cells of the aortic valve, which in time
leads to increased cellularity and proteoglycan deposition in the valves,
ECMdisorganization andHVD.10
Here we present three additional families with an autosomal
recessive HVD primarily affecting the semilunar valves and novel,
homozygous, presumed LoF variants in ADAMTS19. Our findings con-
firm the causative role of ADAMTS19 variants for congenital HVD and
consolidate the related human cardiac phenotype.
2 | METHODS
All five family members (index, parents, affected and unaffected siblings)
from family 1, the index patient from family 2 and index and affected sib-
ling from family 3 were exome sequenced at CENTOGENE AG (Rostock,
Germany), as previously described.11 Libraries were sequenced on an
Illumina Hiseq 4000 with 150 bp paired end sequencing. Variant calling
was performed using GATK. Variants with a phred-scaled quality scor-
e > 21512 and a MAF of <1% were retained for analysis. Variants were
further filtered based on zygosity and segregation in the family, with the
assumption that a causal variant was segregating in an autosomal reces-
sive manner (heterozygous in parents, homozygous or compound het-
erozygous in affected offspring and wild type or heterozygous in the
unaffected sibling). For family 3, only ADAMTS19 and genes from a CHD
panel were evaluated (CFC1, CITED2, CRELD1, FOXH1, GATA4, GATA6,
GDF1,NKX2-5,NOTCH1, TBX1, TBX20, ZFPM2).
Our database CentoMD13 was queried for rare variants (<1%) in
ADAMTS19 (9 September 2019) and the resulting data was filtered
taking into consideration an autosomal recessive mode of inheritance
and the impact of the variant (LoF were prioritized).
The variant-containing exons of ADAMTS19 (NM_133638.4)
were amplified (primers available upon request) and Sanger-
sequenced from both sides on a 3730xl sequencer (Thermo Fisher Sci-
entific, Waltham, Massachusetts) in all available family members for
co-segregation analysis.
Informed written consents were obtained from patients' parents
and referring clinicians. All studies were performed within the exome
sequencing diagnostic procedures.
3 | RESULTS
3.1 | Family 1
The index patient is a 7-year-old female born to healthy, consanguineous
(second-cousins) parents, with no relevant family medical history. She
was born after an uneventful full-term pregnancy with normal delivery.
During her first year of life, she had recurrent respiratory infections and
around the age of 10 months, a murmur was noticed during pediatric
consultation. Echocardiography showed thickened and doming aortic
valve leaflets and subaorticmembrane (SAM). She underwent surgical re-
section of the SAM at the age of 16months. She had recurrent SAM that
required a re-intervention at the age of 3 years. Recently, echocardiogra-
phy showed again a recurring SAMwith very thickened and doming aor-
tic valve leaflets (tri-commissural with partial commissural fusion), mild
aortic insufficiency, and severe left ventricular outflow tract (LVOT)
obstruction. She had doming pulmonary valve leaflets (bi-commissural)
with mild insufficiency. Additionally, she had severe left ventricular
hypertrophy with good biventricular systolic function. Currently she has
mild intermittent symptomsmainly consisting of chest pain during exces-
sive playing. Her psychomotor development is appropriated for her age.
She is currently under regular follow-up by the cardiologist. A future car-
diac intervention is planned (Ross-Kono procedure).
Her brother is a 4-year-old boy who was found to have SAM and
ventricular septum defect (VSD) since birth. The VSD closed sponta-
neously. He then received a follow-up for the SAM and LVOT
obstruction. Echocardiography showed a small SAM, moderate aortic
valve stenosis, mild aortic valve insufficiency, trivial tricuspid valve
insufficiency, and good left ventricular systolic function. No other
abnormalities were reported. Surgical repair (SAM resection) was per-
formed successfully at the age of 3 years. He is clinically asymptom-
atic with good activity tolerance. Figure 1A1, C summarizes the
genealogical tree and echocardiography findings in this family.
3.2 | Family 2
The index case is a 9-year-old female born to consanguineous parents.
There is family history of short stature. She was born prematurely at
34 weeks of gestation by emergency cesarean section because of
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intrauterine growth retardation (IUGR) and fetal distress. She was admit-
ted to the neonatal intensive care unit given her prematurity, IUGR, and
periventricular leukomalacia. She was found to have a heart murmur and
diagnosed with severe pulmonary valve stenosis and small atrial septal
defect (ASD) secundum with tiny persistent ductus arteriosus (PDA). She
had delayed motor milestones; at 7 months old, she was not able to sit
F IGURE 1 Family trees, and associated ADAMTS19 genotypes showing full co-segregation with the cardiac phenotype. All patients are
homozygotes for LoF variants in ADAMTS19. LoF, loss of function. A1, Family 1 pedigree with parents, healthy sibling, index and brother included.
B1, Corresponding Integrative Genomics Viewer (IGV)14 images are shown (NM_133638.4(ADAMTS19):c.2003+1G>T). C, Echocardiography
views in long axis and five chambers planes for the brother (a, b) and the index (c, d) showing the presence of SAM (arrow) under the aortic valve.
Ao, aorta; LA, left atrium; LV, left ventricle; RV, right ventricle. A2, Family 2 pedigree with parents, index and affected sibling included. B2, IGV
images from the index and a control individual and Sangers traces for index and a control individual are shown (NM_133638.4(ADAMTS19):
c.3538C>T, p.Arg1180*). A3, Family 3 pedigree with parents (not tested), index and affected sister. B3, IGV images from index, affected sibling
and a control individual (NM_133638.4(ADAMTS19):c.1957C>T, p.(Arg653*)). D, Index 2D echocardiography, apical view, detailed on valvular
apparatus *:subvalvular aortic stenosis (a). Color Doppler echocardiography, showing disturbances of the aortic flow. AS, aortic stenosis; MI,
mitral insufficiency (b). Affected sister: 2D echocardiography, parasternal long axis. Ao, dilated ascending aorta. *: subvalvular aortic stenosis; x,
thickened mitral valve (a). Color doppler echocardiography. AoI, aortic insufficiency (b). E, Schematic representation of ADAMTS19 gene (following
Ensemble genome browser15) and identified causative variants by Wünnemann et al and the current study [Colour figure can be viewed at
wileyonlinelibrary.com]
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with support. However, at the age of one, she was able to stand and walk
with support and spoke six to seven words. During a physical examina-
tion scaphocephaly, short and upslanting palpebral fissures were noticed.
Currently, she has normal neurodevelopment and remains asymptomatic.
The renal ultrasound was normal. The brain MRI showed delayed mye-
lination and minimal cerebral atrophic changes. The skeletal survey
showed scaphocephaly, normal bone density and delayed bone age. A
chromosomal microarray (CMA) was performed with normal results.
Her younger brother was referred at age of 5½ months, because
of dysmorphic facial features and CHD. He was born at term by a
cesarean section. He displayed feeding difficulties from birth. A small
ASD secundum and mild pulmonary stenosis were detected. He also
had laryngeal cleft type 1 and bronchial asthma. He presented neu-
rodevelopmental delay and autism spectrum disorder. At his last
examination at 2 years old, he had speech delay (able to say only two
words) and just started to walk. CMA was performed and showed a
pathogenic deletion at chromosome 16p11.2 (1 copy loss) consistent
with the chromosome 16p11.2 microdeletion syndrome. The deletion
occurred de novo (both parents had normal CMA). Figure 1A2 shows
the summarized genealogical tree of family 2.
3.3 | Family 3
The index is an 11-year-old female born to consanguineous parents.
Medical family history is positive; a sister of the mother of the index
was diagnosed with an unspecified congenital heart malformation. The
index was born at 38 weeks gestation after an uneventful pregnancy
and delivery, with a birthweight of 2755 g. In the first days, feeding
problems occurred, and 3 days after birth a heart murmur was noticed.
Echocardiography revealed a severe pulmonary valve stenosis due to a
small pulmonary valve orifice with dysplastic and thickened pulmonary
valve leaflets. The right ventricle showed hypertrophy. Also, a milder
valvular aortic stenosis was observed with thickened atrioventricular
valves with mild insufficiency (mitral and tricuspid valve). A patent fora-
men ovale (PFO) with left to right shunting was present. Despite balloon
valvuloplasty at the age of 3 months a substantial pulmonary valve ste-
nosis remained. At the age of 2 years, a severe subaortic valve stenosis
was observed, with moderate aortic valve insufficiency. At this time, the
child had no physical complaints. At the age of 6, complaints of fatigue
were present and pulmonary valve commissurotomy was performed
with resection of a SAM and closure of the PFO. After surgery a mild
valvular and subvalvular aortic stenosis, mild aortic valve insufficiency,
and moderate pulmonary valve stenosis with mild insufficiency
remained without ventricular hypertrophy and normal right and left ven-
tricular systolic function.
The second female child was born at term after an uneventful
pregnancy and delivery with a birthweight of 3460g. She was diag-
nosed with severe pulmonary valve stenosis and mild aortic valve ste-
nosis and insufficiency. At the age of 1 month, a successful balloon
valvuloplasty of the pulmonary valve was performed. At the age of 5,
a mildly dilated ascending aorta (23mm, Z-score+3.6) was present.
Figure1A3 shows the summarized genealogical tree of the family and
echocardiography findings (Figure 1D).
CMAs were performed in both affected siblings, including SNP array
analyses. In both girls, a maternally inherited 1074 kb duplication on band
3p12.3 and a maternally inherited 246 kb deletion on band 6q12 were
present. Both copy number variations were of unknown clinical signifi-
cance. Large regions of copy-neutral homozygosity were observed in
both siblings. NGS-based analysis of a panel of genes related to CHD
resulted negative.
A summary of the most relevant clinical features is presented in
Table 1.
3.4 | Genetic findings
In two families, exome sequencing was requested given the suspicion of
an underlying autosomal recessive condition. Exome analysis did not
reveal any diagnostic candidate variant. However, in family 1 an extended
search beyond approved “diagnostic genes” detected a homozygous vari-
ant in a candidate gene (ADAMTS19). The gene is not described in OMIM
as related to any phenotype (accessed January 9, 2020). Recently, LoF var-
iants in the ADAMTS19 gene were described as causing non-syndromic
HVD, consisting of thickened pulmonary and aortic valves, causing valve
stenosis and insufficiency.10 In family 1, the detected variant was affecting
the canonical splicing site (NM_133638.4:c.2003+1G>T, p.?) and was
found to co-segregate with the HVD phenotype (Figure 1A1,B1). This
splice donor variant is predicted to lead to either skipping of the associated
exon 12 or read through into the intron. Both scenarios result in frame-
shifts and LoF of theADAMTS19 allele.
We searched our database CentoMD13 for rare, presumed LoF vari-
ants in ADAMTS19 and identified one additional patient with a novel
homozygous variant in ADAMTS19(Figure 1A2). In this family (family 2),
the initial exome sequencing request resulted negative (2018). Upon
database queried, a homozygous nonsense variant (NM_133638.4:
c.3538C>T, p.Arg1180*) was detected in the index case (Figure 1B2).
Carrier testing in parents and the affected sibling confirmed co-
segregation of the variant with the cardiac phenotype (homozygous in
index and affected sibling and heterozygous in parents, Figure 1A2,B2).
Family 3 was identified independently via collaboration with the
department of Clinical Genetics (Erasmus University Medical Centre, the
Netherlands). Both patients from family 3 were selected for ADAMTS19
sequencing based on their specific HVD phenotype, and shared region of
homozygosity on chromosome 5 comprising the ADAMTS19 gene. Sub-
sequently, targeted NGS analysis of the gene revealed a homozygous
LoF variant, NM_133638.4:c.1957C>T, p.(Arg653*) in both affected indi-
viduals (Figure 1A3,B3).
All three variants were absent from gnomAD (last accessed Janu-
ary 9, 2020) and detected for the first time in homozygous state in
the CentoMD database. Disease causing ADAMTS19 variants reported
to date are summarized in Figure 1E.
4 | DISCUSSION
In this study, we present further evidence confirming that biallelic LoF
ADAMTS19 variants cause a CHD affecting mainly the semilunar
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valves. We report three additional LoF variants in six patients from
three families and describe the associated phenotype.
In this study, most reported abnormalities include aortic/pulmo-
nary valve thickening, stenosis, and insufficiency. In addition to semi-
lunar valve abnormalities, three out of six patients in our study and
one patient described previously10 presented with (recurrent) SAM.
SAM is a shelf-like membrane that forms below the aortic valve, con-
sisting of several tissue layers including glycosaminoglycans in the
subendothelial layer.16 SAM results in subaortic stenosis and
increased pressure gradient in the LVOT, it has unpredictable hemo-
dynamic progression in childhood and high reoperation rate in up to
34% of patients.16,17 Histopathology of SAM in studied families
showed fibromuscular tissue fragments exhibiting secondary regen-
erative changes on a myxoid background and hypercellularity. These
histopathological findings show similarity to those described in
Adamts19KO/KO mice including hypercellularity, cellular debris,
smaller collagen type I fibers and abundant proteoglycans.10 It was
hypothesized that loss of Adamts19 perturbs shear stress signaling
in the endothelial cell leading to increased cellularity and proteogly-
can deposition, with increased molecular shear stress signature
shown both at scRNA and protein level.10 Three out of the six
patients reported in this study which had homozygous LoF
ADAMTS19 variants, presented SAM with concomitant aortic valve
stenosis. SAM reoccurred after surgical resection in two cases,
suggesting that in time, hemodynamic factors in combination with
loss of ADAMTS19 can lead to SAM recurrence (II-2, family 1 and
II-1, family 3). Autosomal recessive and dominant inheritance of
SAM was suspected as described occasionally, co-occurring with
aortic valve stenosis within families but no gene defect had been
recognized to date.18-20ADAMTS19 is the first gene identified
related to discrete subaortic stenosis.
In contrast to the reported BAV phenotype in 2/4 patients and
the Adamts19KO/KO mice by Wünnemann et al, none of the current
patients were reported to have BAV. However, one patient presented
with bi-commissural pulmonary valve, which was not described in pre-
vious cases. Aortic and pulmonary valve stenosis and insufficiency
were common features among all patients. In addition to abnormali-
ties of the semilunar valves, 3/6 patients in our study and 2/4 patients
from Wünnemann et al also presented with mild involvement of the
atrioventricular valves, which contrasted with the absence of atrio-
ventricular valve abnormalities in the Adamts19KO/KO mice. Adamts19
is expressed in both semilunar and atrioventricular valves from E14.5
until adulthood in mice.10
In general, the phenotype described within this study seems more
severe than previously reported, with 2/6 patients presenting with
cardiac related complaints. Additionally, while no extracardiac features
were described in previous cases,10 some of our patients presented
with additional features, such as facial dysmorphism (4/6 patients
with upslanting palpebral fissures) and delay in language/motor devel-
opment (2/6 patients, Table 1). In one of these patients (II-3, family 2),
a concomitant 16p microdeletion (de novo) was detected which
explains the neurological phenotype. Given the consanguinity
reported in family 2, we cannot exclude that unidentified variants are
causing additional phenotypic features. However, exhaustive exome
analysis did not reveal any additional relevant variant.
The cardiac phenotype in our patients and the patients described
by Wünnemann et al seems to differ from Notch1-related aortic valve
disease: no calcification was observed so far (although all patients are
relatively young), no other left side heart defects are present (such as
hypoplastic left ventricle) and SAM or subaortic stenosis is never
described in Notch-related heart disease.21
ADAMTS comprise a family of 19 secreted, extracellular enzymes
with a common multidomain structure. The evolutionary conservation of
this protein family suggests that they are crucial for mammalian physiol-
ogy, as shown by the strong phenotypes compromising morphogenesis
and relevant functions in humans and mice.22,23 As registered in OMIM
(accessed January 9, 2020), members of the ADAMTS family are
involved in several genetic diseases: Ehlers-Danlos syndrome, derma-
tosparaxis type (ADAMTS2), Hennekam lymphangiectasia-lymphedema
syndrome type 3 (ADAMTS3), Weill-Marchesani syndrome type
1 (ADAMTS10), familial thrombotic thrombocytopenic purpura
(ADAMTS13), Weill-Marchesani syndrome type 4 (ADAMTS17) and mic-
rocornea, myopic chorioretinal atrophy, and telecanthus (ADAMTS18).
Furthermore, based on a recent report, ADAMTS16 might be implicated
in LVTO obstruction with extracardiac anomalies24 and ADAMTS6 in car-
diac conduction defects.25
Similarly, Adamts spontaneous and engineered disease models
in rodents have been described for 11 Adamts genes.10,23 This is
not the first time that a gene from this family has been linked to
cardiac abnormalities. Kern et al described cardiac and aortic anom-
alies in adult haploinsuficient mice (Adamts9+/LacZ), probably
related to reduced versican cleavage.26 Recently, Dupuis et al
reported anomalies of the ascending aorta such as increased aortic
thickness and aortic stenosis in Adamts5 deficient mice, probably
due to perturbation of Adamts5-mediated cleavage of its proteo-
glycan substrate aggrecan.27 Altogether, these results point toward
an important role of several members of the ADAMTS family in car-
diovascular health.
4.1 | Limitations of the study
During this study, we only detected pediatric patients. Further follow-
ups and detection of adult patients is needed to better understand
the evolution and progression of the ADAMTS19 related disease.
In conclusion, we confirm that LoF variants in ADAMTS19 are
causative of a specific cardiac phenotype, characterized mainly by
stenosis and insufficiency of the semilunar heart valves. Additionally,
the atrioventricular valves are affected in half of the cases, with arte-
rial dilatations occurring occasionally. We conclude that pathogenic
ADAMTS19 variants lead to a recognizable cardiac phenotype. Fur-
thermore, we recommend considering ADAMTS19 genetic testing in
all patients with multiple semilunar valve abnormalities, particularly
in the presence of SAM. This would guide further cardiological
screening and follow-ups of the patients and relatives. Finally,
ADAMTS19 screening in cohorts of patients with semilunar valve
MASSADEH ET AL. 7
abnormalities is needed to estimate the frequency of the HVD
related phenotype, which might be not so rare.
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